A prospective, randomized, double dummy, double blind, multi-center multinational trial comparing the efficacy and safety of moxifloxacin 400 mg PO QD 24 hours for 14 days to that of levofloxacin 500 mg PO QD 24 hours plus metronidazole 500 mg BID for 14 days in subjects with an uncomplicated pelvic inflammatory disease. Moxifloxacin, metronidazole, and levofloxacin in Asia (MONALISA study).

Trial Profile

A prospective, randomized, double dummy, double blind, multi-center multinational trial comparing the efficacy and safety of moxifloxacin 400 mg PO QD 24 hours for 14 days to that of levofloxacin 500 mg PO QD 24 hours plus metronidazole 500 mg BID for 14 days in subjects with an uncomplicated pelvic inflammatory disease. Moxifloxacin, metronidazole, and levofloxacin in Asia (MONALISA study).

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Moxifloxacin (Primary) ; Levofloxacin; Metronidazole
  • Indications Bacterial infections; Gynaecological infections; Pelvic inflammatory disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms MONALISA
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 10 Oct 2009 Results reported at FIGO World Congress.
    • 10 Oct 2008 Bayer HealthCare reported as trial affiliate by ClinicalTrials.gov.
    • 07 Oct 2008 Actual number of patients (460) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top